These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25877809)

  • 1. New Oral Anticoagulants and Their Reversal.
    Pinto I; Giri A; Arshad U; Gajra A
    Curr Drug Saf; 2015; 10(3):208-16. PubMed ID: 25877809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm.
    Palaiodimos L; Miles J; Kokkinidis DG; Barkolias C; Jonnalagadda AK; Papaconstantinou D; Frountzas M; Misiakos EP; Schizas D
    Curr Pharm Des; 2018; 24(38):4540-4553. PubMed ID: 30585542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidotes for novel oral anticoagulants: current status and future potential.
    Crowther M; Crowther MA
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1736-45. PubMed ID: 26088576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
    Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
    Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
    Hirschl M; Kundi M
    Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).
    Capodanno D; Giacchi G; Tamburino C
    Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):2-9. PubMed ID: 23597292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bleedings under NOAC (non Vitamin-K dependent oral anticoagulants). Evidence and practical management].
    Koscielny J; Rutkauskaite E
    Hamostaseologie; 2015; 35 Suppl 1():S43-53. PubMed ID: 26540130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative use of prothrombin complex concentrates.
    Colomina MJ; Díez Lobo A; Garutti I; Gómez-Luque A; Llau JV; Pita E
    Minerva Anestesiol; 2012 Mar; 78(3):358-68. PubMed ID: 22357373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
    Dickneite G; Hoffman M
    Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.
    Husted S; Verheugt FW; Comuth WJ
    Drug Saf; 2016 Jan; 39(1):5-13. PubMed ID: 26519420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.